# Impact BioMedical, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Impact BioMedical, Inc). ## Overview Impact Biomedical Inc. is a U.S.-based early-stage biopharmaceutical and wellness company that discovers, patents, and seeks to commercialize proprietary science through external partners. Its model centers on licensing, co-development, joint ventures, and selective direct sales across healthcare, consumer wellness, and air-purification products. ## Products & services • Licensed biopharmaceutical and wellness technologies • Laetose consumer/biopharma ingredient platform • Equivir antiviral platform • Celios air purification technology • Functional Fragrance Formulation (3F) • Patent licensing, co-development, and JV commercialization - **Biopharmaceutical platforms** (10%) — Patented science and drug-discovery assets aimed at neurological, oncologic, inflammatory, antiviral, and antimicrobial uses. - **Consumer wellness ingredients and products** (20%) — Over-the-counter and direct-to-consumer wellness offerings, including Laetose and related formulations. - **Air purification products** (60%) — Celios-branded air purification technology sold through online and distributor channels. - **IP licensing and commercialization partnerships** (10%) — Licensing, co-development, milestone, and royalty arrangements used to monetize patents and technologies. - Licensed biopharmaceutical and wellness technologies - Laetose consumer/biopharma ingredient platform - Equivir antiviral platform - Celios air purification technology - Functional Fragrance Formulation (3F) - Patent licensing, co-development, and JV commercialization ## Customers The company sells primarily to commercial partners rather than end consumers, using licensing and co-development to monetize its intellectual property. Its customer base includes pharmaceutical companies, consumer packaged goods companies, food companies, and distributors that can commercialize its technologies. For its Celios product line, it also reaches retail and online buyers through third-party distribution channels. - **Pharmaceutical licensing partners** (primary) — Buy rights to IBO technologies for development and commercialization in exchange for milestones and royalties. - **Consumer packaged goods and food companies** (primary) — License wellness, ingredient, or formulation technologies for branded consumer products. - **Distribution and retail channels** (secondary) — Purchase Celios air purification products for resale through online and third-party networks. - **Co-development and joint venture partners** (primary) — Collaborate on product development and commercialization to reduce funding and execution burden. - Pharmaceutical partners seeking licensed drug-discovery assets - Consumer packaged goods companies for wellness and ingredient products - Food companies interested in functional ingredients and formulations - Distributors and online channels for Celios air purification sales - Potential co-development partners that fund development and commercialization ## Geography Impact Biomedical is headquartered in the United States and conducts most of its business through U.S.-issued patents, U.S. corporate operations, and U.S.-based capital markets access. The company also states that it has patent coverage and pending applications in countries worldwide, which supports future international licensing and commercialization. Its current revenue disclosure is product-based rather than country-based, so geographic revenue concentration is not disclosed. - Headquartered and listed in the United States - Patents issued in the U.S. and other countries worldwide - Commercialization is intended to be global through partners - Current sales are small and not broken out by country - International patent coverage supports future licensing reach ## Strategy The company’s strategy is to monetize its patent portfolio by pairing proprietary science with external partners that can fund development, manufacturing, and commercialization. Recent disclosures show a push to broaden the portfolio with Celios and other technologies while seeking a merger structure and capital to support a larger commercial platform. Management also emphasizes cost control and intellectual-property monetization to keep the business funded as a going concern. - **Commercialize existing IP through partners** (short-term) — The company lacks scale to self-fund broad development and relies on partners for monetization. - **Expand the product portfolio with acquired technologies** (medium-term) — New assets can create faster revenue opportunities and diversify the IP base. - **Strengthen the capital structure and public-market platform** (short-term) — The company needs funding and a stronger operating base to continue development and commercialization. - Monetize patents through licensing, royalties, and milestones - Use co-development and JVs to reduce capital intensity - Expand the portfolio with Celios and other acquired technologies - Pursue a reverse merger to accelerate scale and market access - Control operating costs while seeking new capital - Convert IP into near-term revenue opportunities ## Risks Impact Biomedical is highly dependent on successful patent protection, partner execution, and access to capital, which makes the business model inherently speculative. Development, regulatory, and manufacturing risks are amplified because the company relies on third parties for clinical supplies and commercialization, while current revenue remains minimal. As an early-stage IP company, it also faces going-concern, dilution, and impairment risk if monetization efforts do not scale. - **Intellectual property challenge or loss** [high] — The business depends on patents and trademarks to create licensing value and defend products. - **Partner execution and commercialization failure** [high] — Revenue depends on external partners agreeing to license, develop, and distribute products. - **Regulatory and clinical development delays** [high] — Drug candidates require lengthy trials and regulatory review before commercialization. - **Going-concern and financing risk** [critical] — The company has limited revenue and has stated it may need additional capital to continue operations. - **Third-party manufacturing dependence** [medium] — The company does not internally manufacture drug candidates and relies on outside suppliers. - Patent protection may be challenged, narrowed, or invalidated - Commercialization depends on third-party partners and distributors - Clinical and regulatory timelines can delay or block product approval - Third-party manufacturing creates supply and quality risk - Limited revenue and funding raise going-concern and dilution risk ## Accounting The most important accounting issue is the valuation and recoverability of acquired and developed intangible assets, including patents, goodwill, and new product lines. Revenue is currently small and appears tied to retail sales of Celios, so investors should watch how the company recognizes product revenue versus licensing or milestone income as commercialization evolves. The company also has meaningful judgment areas around debt conversion, fair value adjustments, stock-based compensation, and impairment testing. - **Revenue recognition for product sales and licensing arrangements** — Affects timing and classification of revenue - **Impairment of goodwill and intangible assets** — Can create large non-cash charges if expected cash flows weaken - **Fair value measurement of debt and conversion features** — Can materially affect net loss and equity - **Stock-based compensation and professional fees** — Influences operating expense run-rate and comparability - Revenue recognition may shift between product sales and licensing income - Goodwill and intangible assets are exposed to impairment risk - Debt conversion and fair value adjustments can affect reported results - Stock-based compensation and professional fees can distort operating trends - Small revenue base makes quarter-to-quarter comparisons volatile --- *Last updated: 2026-09-24T12:21:02.981954+00:00*